PhaseRx, Inc.

This year's tally of biopharmaceutical initial public offerings in the US was tied with 2016's total of 30 IPOs when Rhythm Pharmaceuticals Inc. went public on Oct. 5, but 2017 outpaced last year

RNA-based medicines have had a checkered development history, including a mixed bag of results last year at some of the leading players such as Alnylam Pharmaceuticals Inc. and Moderna Therapeut

Generalist investors that gambled on the US biopharmaceutical initial public offering market between 2013 and mid-2015 are largely gone, leaving health care specialists to bet on less risky drug devel

TiGenix NV ’s Dec. 14 initial public offering was the first biopharmaceutical IPO this month and the 30th for the year, but while 2016 has seen half as many IPOs as 2015, the new crop of publicly tra